Logo del repository
  1. Home
 
Opzioni

Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

ZAJA, Francesco
•
BATTISTA ML
•
PIRROTTA MT
altro
FANIN, Renato
2008
  • journal article

Periodico
HAEMATOLOGICA
Abstract
Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50×10 9/L) and complete responses (platelet count > 100×10 9/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose
DOI
10.3324/haematol.12206
WOS
WOS:000256538100021
Archivio
http://hdl.handle.net/11368/2953657
info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-44949126978
Diritti
metadata only access
Web of Science© citazioni
77
Data di acquisizione
Mar 24, 2024
Visualizzazioni
1
Data di acquisizione
Apr 19, 2024
Vedi dettagli
google-scholar
Get Involved!
  • Source Code
  • Documentation
  • Slack Channel
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your nstitution's web identity.

Need professional help?

The original creators of DSpace-CRIS at 4Science can take your project to the next level, get in touch!

Realizzato con Software DSpace-CRIS - Estensione mantenuta e ottimizzata da 4Science

  • Impostazioni dei cookie
  • Informativa sulla privacy
  • Accordo con l'utente finale
  • Invia il tuo Feedback